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The citric acid cycle (CAC) metabolite fumarate has
been proposed to be cardioprotective; however, its
mechanisms of action remain to be determined. To
augment cardiac fumarate levels and to assess
fumarate’s cardioprotective properties, we gener-
ated fumarate hydratase (Fh1) cardiac knockout
(KO) mice. These fumarate-replete hearts were
robustly protected from ischemia-reperfusion injury
(I/R). To compensate for the loss of Fh1 activity, KO
hearts maintain ATP levels in part by channeling
amino acids into the CAC. In addition, by stabilizing
the transcriptional regulator Nrf2, Fh1 KO hearts
upregulate protective antioxidant response element
genes. Supporting the importance of the latter mech-
anism, clinically relevant doses of dimethylfumarate
upregulated Nrf2 and its target genes, hence pro-
tecting control hearts, but failed to similarly protect
Nrf2-KO hearts in an in vivo model of myocardial
infarction. We propose that clinically established
fumarate derivatives activate the Nrf2 pathway and
are readily testable cytoprotective agents.
INTRODUCTION
The observation that exposing hearts to brief, repeated
episodes of ischemia renders them resistant to the sequelaeCeof prolonged I/R has triggered the search for pharmacological
agents, including metabolic agents, that recapitulate this cardi-
oprotection (Yellon and Hausenloy, 2007). Although the litera-
ture relating metabolism to cardioprotection is dominated by
accounts of carbohydrate metabolism (Howell et al., 2011),
other metabolites, such as amino acids and citric acid cycle
(CAC) intermediates, also contribute to the myocardial
response to ischemia. Previous studies have reported that
the hypoxic/ischemic myocardium converts aspartate and
glutamate to succinate via the CAC (Figure 1), yielding ATP
and GTP (Hochachka et al., 1975; Taegtmeyer, 1978; Sanborn
et al., 1979; Hohl et al., 1987). This channeling of amino acids
through the CAC has been proposed to be beneficial by virtue
of its capacity to maintain redox potentials and to yield high-
energy phosphates. However, despite the plausibility of these
pathways (Penney and Cascarano, 1970), their contribution to
I/R and cardioprotection in the mammalian heart remains
contentious (Sanborn et al., 1979; Peuhkurinen et al., 1983;
Hohl et al., 1987; Wiesner et al., 1988; Penney and Cascarano,
1970).
Recognizing the central role of fumarate to the above pathway,
Des Rosiers and colleagues studied metabolic fluxes in fuma-
rate-perfused rat hearts (Laplante et al., 1997). While this study
substantiated the potentially cardioprotective influence of exog-
enous fumarate, it raised a number of questions. As the kinetic
characteristics of the mammalian dicarboxylate transporter are
poorly understood (Gallagher et al., 2009), the 0.04–0.4 mM of
fumarate in the perfusate may not have optimally raised intracel-
lular fumarate levels, resulting in relatively modest cardiopro-
tection. Moreover, since the yield of ATP directly derived from
fumarate metabolism was 100-fold lower than the rate of lactatell Metabolism 15, 361–371, March 7, 2012 ª2012 Elsevier Inc. 361
Figure 1. A Summary of Metabolic Pathways Relating to the CAC
Carbons derived from amino acids contribute to citric acid cycle (CAC) flux (anaplerosis), reducing NAD+ to NADH and ultimately yielding ATP. To maintain this
energy-yielding flow, especially in the context of CAC interruption and during hypoxia/ischemia, carbon moieties must exit the CAC, e.g., through succinate and
succinyl CoA.
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to account for fumarate’s cardioprotective properties (Penney
and Cascarano, 1970; Peuhkurinen et al., 1983). These included
fumarate’s putative capacity to preserve cellular redox potential,
improve calcium homeostasis, decrease free radical production,
and reduce toxic acyl-CoA derivative accumulation during I/R
(Laplante et al., 1997).
To increase myocardial fumarate concentrations and to
permit delineation of the mechanisms through which fumarate
might confer cardioprotection, we began by generating a mouse
model of fumarate augmentation. We used a gene-targeted
mouse with loxP sequences flanking exons 2 and 3 of the
fumarate hydratase gene (Fh1)—Fh11fl/fl (Pollard et al., 2007).
Inactivation of Fh11 in the kidney achieved by crossing Fh11fl/fl
mice with mice expressing Cre recombinase under the Ksp-
cadherin promoter (Ksp1.3/Cre) resulted in healthy animals
despite substantially increased fumarate concentrations
(Pollard et al., 2007; Ashrafian et al., 2010). Reassured by this
unexpectedly mild phenotype, we similarly inactivated cardiac
Fh11 (specifically in cardiomyocytes) by breeding Fh11fl/fl
mice with mice expressing Cre recombinase under the cardio-
myocyte-specific promoter of myosin light chain—(MLC2v)-Cre
(Chen et al., 1998). We sought to (1) assess whether cardiac
function is maintained despite Fh1 inactivation in Fh11fl/fl
MLC2v-Cre hearts and whether they exhibit increased fumarate
levels, (2) determine whether these hearts are protected against
I/R, (3) investigate the metabolic and other mechanisms of car-
dioprotection, and finally (4) ascertain whether any of the bene-
ficial effects are directly attributable to fumarate by assessing
the cardioprotective effects of exogenous oral fumaric acid
derivatives (FADs) in nontransgenic animals experiencing I/R
in vivo.362 Cell Metabolism 15, 361–371, March 7, 2012 ª2012 Elsevier Inc.RESULTS
Cardiac Structure and Function Are Comparable in Fh1
Knockout and Control Mice
To understand the consequences of cardiac fumarate aug-
mentation Fh1fl/fl MLC2v-Cre (termed Fh1 KO) (Figure 2A),
Fh1fl/+ MLC2v-Cre and Fh1fl/fl (termed controls and indistin-
guishable from wild-type [WT] controls) were observed to be
healthy until 3 months of age, when they develop ventricular
dysfunction—the metabolic and redox basis of which is the
subject of ongoing investigation. Experiments were therefore
performed in 6-week-old mice. Immunoblotting confirmed
depletion of Fh1 protein in Fh1 KO mice compared to controls
(29% ± 8% versus 100% ± 16%; p < 0.05) (Figure 2B). The re-
maining protein reflects persisting Fh1 in the nonmyocyte
compartment (in which Cre is not expressed), as Fh1 transcript
and protein are almost completely absent from isolated Fh1 KO
cardiomyocytes (Figure 2C). Substantial metabolic differences
exist between the Fh1 KO and control mice (see Figure S2
and Table S1 online), including a significant increase in
whole-heart fumarate levels in Fh1 KO animals as derived
from 1D 1H NMR spectroscopy (Fh1 KO:control ratio, 1.63:1;
p < 0.005). Despite the Fh1 depletion, cardiac structure and
function including myocyte size (Figure 2D), heart weight:body
weight ratio (Figure 2E), and ejection fraction (Figure 2F), as
well as function assessed by cine MRI (data not shown), were
similar in young Fh1 KO and controls. Heart rate, blood pres-
sure (Figure 2G), and comprehensive assessment of LV func-
tion in vivo were comparable between both groups. The only
difference was in the LV end-diastolic pressure, which
decreased greater with dobutamine in Fh1 KO compared to
controls (at baseline, 5.61 ± 1.52 versus 10.06 ± 3.74; after
Figure 2. Fh1 KO Hearts Are Anatomically
andPhysiologically Comparable toControls
(A) Fh1fl/fl mice (Pollard et al., 2007) were crossed
with mice expressing Cre recombinase under the
promoter of myosin light chain, (MLC2v)-Cre
(Chen et al., 1998), to generate heterozygous and
homozygous knockout (KO) mice.
(B) Assessed at 5–6 weeks of age, Fh1 KO hearts
had substantially reduced Fh1 protein levels as
demonstrated by the representative immunoblots
and densitometric analysis (29% of controls).
(C) Isolated cardiomyocytes in Fh1 KO had
complete depletion of Fh1 protein.
(D and E) Fh1 KO hearts were comparable to
controls, with no evidence of cellular hypertrophy
as assessed by wheat germ agglutinin (WGA) and
gross hypertrophy.
(F) Systolic cardiac function as assessed by
echocardiographic left ventricular ejection fraction
was comparable between KO and control hearts.
(G and H) Invasive assessment of blood pressure
and of contractile function revealed that Fh1 KO
hearts were comparable to controls except with
respect to LVEDP (H), which decreased in Fh1 KO
hearts with increasing doses of dobutamine. B,
controls; x, HET KO;C, Fh1 KO.
(I) Fh1 KO hearts exhibited comparable baseline
energetics to controls as assessed by 31P-MRS.
Values are mean ± SEM. *p < 0.05 versus Fh11fl/fl
mice.
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p < 0.05) (Figure 2H).
Energetics in Fh1 KO hearts were comparable to controls as
assessed by 31P-MRS measurement of the PCr:ATP ratio in
perfused hearts (2.23 ± 0.20 versus 2.02 ± 0.12) (Figure 2I).
Fh1 KO Mice Are Protected from Ischemia-Reperfusion
Injury
Using a perfused heart model of ischemia/reperfusion (I/R), we
investigated the response of Fh1 KO and controls to global
cardiac ischemia. We employed a relatively long (40 min) period
of ischemia, as young hearts are more tolerant of ischemia (Wil-
lems et al., 2005)—shorter (30 min) periods of ischemia had
similar effects (data not shown). The degree of necrosis
expressed as percentage of total at risk myocardium (i.e.,
ventricular volume) was substantially decreased in the Fh1
KOs compared to controls (17% ± 4% versus 37% ± 5%; p <
0.005) (Figure 3A). The recovery of coronary flow (CF), an estab-
lished surrogate for reduced I/R injury (Headrick et al., 2001),Cell Metabolism 15, 361–3was increased in the Fh1 KO group
compared to controls after reperfusion
(mean CF, 2.4 ± 0.05 versus 1.7 ±
0.03 ml/min; ANOVA, p < 0.0001) (Fig-
ure 3B), consistent with reduced myocar-
dial necrosis. This reduction in necrosis
was corroborated by significantly
reduced release of markers of myocardial
injury including creatine kinase and
cardiac troponin I (Figures 3C and 3D).
The recovery of function, expressed aspercentage of the initial rate pressure product, was not signifi-
cantly different in Fh1 KO versus controls (97% ± 12% versus
78% ± 6%) (Figure 3E), a dissociation that has been recognized
in cardioprotection (Cohen, 2004). Importantly, no differences
were observed between Fh1 KO and controls in PCr, ATP, or
Pi during the I/R protocol (data not shown).
Myocardial microdialysis was used to systematically profile
the interstitial cardiac metabolite concentrations during the
different phases of I/R. During ischemia, the concentrations of
many CAC intermediates, as previously reported by the same
technique, increased in both Fh1 KO and control hearts (Birkler
et al., 2010). However, the concentrations of succinate and
glutamate were lower in Fh1 KO hearts than in controls—a
pattern that has previously been associated with reduced
myocardial injury (Vincent et al., 2000; Liu et al., 2010). During
ischemia, and in reperfusion, the interstitial purine concentra-
tions increased. However, the adenosine levels were lower in
Fh1 KO hearts compared to controls (Figures 3F–3K). This
pattern of reduced purine metabolism, previously observed in71, March 7, 2012 ª2012 Elsevier Inc. 363
Figure 3. Cardiac Fh1 Deficiency Confers Cardioprotection
(A) Fh1-KO exhibited significant attenuation of myocardial necrosis (determined with TTC staining) compared with control hearts when perfused with 40 min of
no-flow ischemia followed by 120 min of reperfusion.
(B) This was accompanied by substantially better recovery in coronary flow.
(C and D) This reduction in myocardial necrosis was confirmed by a significant reduction in markers of cardiac injury (cardiac troponin I, TnI; and creatine
kinase, CK).
(E) Functional recovery as assessed by the rate pressure product was comparable in the Fh1-KOs and controls.
(F–K) Myocardial microdialysis coupled to an ultraperformance liquid chromatography/electrospray-tandem mass spectrometry approach demonstrated
differences in the interstitial concentrations of succinate, glutamate, and adenosine during stabilization, ischemia, and reperfusion between Fh1-KO and control
hearts. Fh1-KO (C) and controls (B). Values are mean ± SEM. *p < 0.05; **p < 0.01 versus control; ***p < 0.001 versus control.
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injury and may indicate inhibition of adenine nucleotide catabo-
lism resulting from the inhibition of 50-nucleotidase activity (Van
Wylen, 1994; Wikstrom et al., 1995).364 Cell Metabolism 15, 361–371, March 7, 2012 ª2012 Elsevier Inc.Anaplerosis by Amino Acids Is a Prominent Adaptation
to Fh1 Deletion
To determine themechanisms of cardiac viability and I/R protec-
tion in hearts lacking Fh1, a critical component of the CAC, we
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Fumarate Cardioprotects via Activation of Nrf2applied a flux balance analysis (FBA) model of mitochondrial
metabolism to predict the consequences of Fh1 depletion (Smith
and Robinson, 2011). The metabolic fluxes for maximal ATP
production were determined on the basis of fixed reaction stoi-
chiometry, reaction directionality accounting for thermodynamic
requirements, protonation state differences between the cytosol
and matrix, and known transport fluxes. This model predicted
that deletion of Fh1, without any adaptations, disrupted flux
around the CAC, causing a 96% drop in ATP production.
However, increased import of glutamate, other amino acids,
and metabolites related to the malate-aspartate shuttle restored
cardiac NAD+ reduction and ATP production (Figure 4A). In
summary, a substantial anaplerotic amino acid flux into the
CAC is predicted to restore both spans of the CAC, maintaining
[NAD+/NADH], oxidative phosphorylation, and energetic
viability. 1D 1H NMR confirmed the perturbation of many of the
metabolites identified in our in silico analysis (Table 1). Although
this steady-state metabolomics is a metabolic snapshot sup-
porting our predictions, inferences about metabolic fluxes are
necessarily limited.
To investigate our metabolic model further, we studied Fh1 KO
cardiac metabolism in vivo with hyperpolarized magnetic reso-
nance spectroscopy using [1-13C]pyruvate and [2-13C]pyruvate
to measure the rate of glycolytic (i.e., pyruvate dehydrogenase
[Pdh] fluxes and lactate dehydrogenase [Ldh]) and CAC fluxes,
respectively (Schroeder et al., 2008, 2009). Although Fh1 KO
hearts manifest increased steady-state lactate levels (Fh1 KO,
control ratio 1.26:1; p = 0.034) (Table 1), consistent with
increased glycolysis in Fh1 KO hearts as in other tissues (Ashra-
fian et al., 2010), no pyruvate flux differences were apparent
between Fh1 KO and control hearts (Figure S4). Finally, to deter-
mine the influence of Fh1 deletion on the metabolic fate of amino
acids, we perfused Fh1 KO and controls hearts ex vivo with
[3-13C]glutamate with subsequent 2D 13C-HSQC NMR analysis.
As expected, fumarate levels were significantly higher in Fh1 KO
hearts. Moreover, supporting the proposal that Fh1 KO hearts
augment amino acid derived flux through the CAC, we observed
significantly increased label incorporation into CAC metabolites
(e.g., aspartate and pyruvate [at C2 and C3], likely by reductive
carboxylation) in Fh1 KO hearts compared to controls
(Figure S5).
Supporting these observations, the expression of mRNA
coding for glycolytic enzymes, biochemical measures of glyco-
lytic enzyme activity, mitochondrial respiratory chain complex
activity, and myofiber oxygen consumption showed no differ-
ences between Fh1 KO and control hearts (Figure S6). Overall,
these metabolic studies reinforce the role of increased amino
acid metabolism as an important mechanism contributing to the
maintenance of CAC activity and hence viability in Fh1KOhearts.
Fh1 KO Hearts Activate the Nrf2 Pathway that Mediates
Cardioprotection
To identify signaling pathways that contribute to cardioprotec-
tion, we used microarray analysis (Table S2) with qRT-PCR vali-
dation of Fh1 KO and control heart mRNA. Canonical Nrf2 target
genes (Kwak et al., 2003; Hayes et al., 2010) and coregulated
genes encoding antioxidant enzymes of one-carbonmetabolism
(Harding et al., 2003) showed prominent differential expression
between Fh1 KO and controls (fold change KO:control is asCefollows: Hmox1, 1.53 ± 0.13, p < 0.01; Nqo1, 1.93 ± 0.2x3,
p < 0.01; Mthfd2, 243 ± 43, p < 0.001; Gsta1, 1733 ± 493,
p < 0.001) (Figure 4B). To assess if this increase in Nrf2-
dependent target genes resulted from a stabilization of Nrf2
protein related to modification of its inhibitor—Kelch-like ECH-
associated protein 1 (Keap1)—immunoblotting was performed.
This confirmed downregulation of Keap1 protein (fold change
KO:control, 0.663 ± 0.053, p < 0.01; despite unchanged
Keap1 mRNA expression levels, Figure S1) and upregulation of
Nrf2 (1.993 ± 0.583, p < 0.05), Hmox1 (2.733 ± 0.713, p <
0.05), Nqo1 (2.243 ± 0.423, p < 0.05), Mthfd2 (19.913 ±
5.943, p < 0.05), Gsta3 (1.73 ± 0.343, p < 0.05), and Gsta1
(149.03 ± 43.73, p < 0.05) proteins, which corresponded well
to the gene expression changes (Figure 4C). To assess whether
the pseudohypoxic properties of fumarate or succinate resulted
in HIF-1a stabilization in this model (Ashrafian et al., 2010), qRT-
PCRwas used to quantify a panel of HIF targets—these were not
raised in Fh1 KO hearts (Figure S1).
Both endogenous (i.e., Fh1 KO) and exogenous fumarate
augmentation in cells have been reported to modify and inacti-
vate Keap1 by modification at cysteines 151 and 288 in vitro
(Linker et al., 2011; Adam et al., 2011; Ooi et al., 2011). To
address whether this ‘‘succination’’ was pertinent to Fh1 KO
hearts in vivo, whole-cell lysates from Fh1 KO and control hearts
were probed with an antibody to S-(2-succinyl)cysteine (2SC)
(Blatnik et al., 2008; Bardella et al., 2011). Fh1 KO hearts had
increased levels of 2SC compared to controls (2.493, p <
0.001) (Figure 4D). These findings, coupled with Keap1’s sensi-
tivity to electrophiles (Taguchi et al., 2011), support the proposal
that Keap1 succination in Fh1 KO hearts is the cause of Nrf2 acti-
vation (Adam et al., 2011; Ooi et al., 2011).
One transcriptional consequence of Fh1 deficiency is Hmox1
upregulation. Since Hmox1 is cardioprotective (Melo et al.,
2002; Piantadosi et al., 2008; Soares et al., 1998; Yet et al.,
2001), we hypothesized that Hmox1 contributed to fumarate-
related cardioprotection and assessed the effect of zinc deu-
teroporphyrin 2,4-bis glycol (ZnBG), a well-established and
relatively specific Hmox1 inhibitor (Vreman et al., 1991; Appleton
et al., 1999; Zhang et al., 2002; Morioka et al., 2006; Czibik et al.,
2009). Inhibition of Hmox1 by ZnBG abrogated cardioprotection
in the Fh1 KO hearts (33.3% ± 2.2% control; 11.4% ± 1.5% Fh1
KO; 30.1% ± 2.7% control + ZnBG; 35.2% ± 4.6% Fh1
KO + ZnBG; Fh1 KO ANOVA p < 0.001 versus all other groups)
(Figure 4E).
Exogenous Fumarate Is Protective against Cardiac
Ischemia-Reperfusion Injury
To investigate whether our observations in our Fh1 KOmodel are
directly attributable to elevated fumarate and amenable to clin-
ical translation, we assessed the consequences of fumarate
augmentation. Mice were gavaged with dimethylfumarate
(DMF) 15 mg/kg twice daily (comparable to a dose well-tolerated
by humans and applicable to clinical practice) for 5 days (Linker
et al., 2011; Kappos et al., 2008). We found that, compared with
the vehicle-treated controls, DMF stabilized and increased Nrf2
protein (1.483 ± 0.153, p < 0.05). Further, using confocal immu-
nofluorescence microscopy, we were also able to demonstrate
that low concentrations of DMF (10 mM) promoted Nrf2 nuclear
translocation in cardiomyocyte-like HL-1 cells (Figure 5A).ll Metabolism 15, 361–371, March 7, 2012 ª2012 Elsevier Inc. 365
Figure 4. Fh1 Deficiency Confers Cardioprotection through Both Increasing Carbon Flux and Upregulating Heme Oxygenase 1 by Nrf2
(A) In silico modeling of optimal metabolic flux distributions for maximal ATP production in Fh1-deficient hearts. In contrast to the normal heart (Figure S3),
reconstituting the CAC around absent Fh1 requires amino acids (e.g., glutamate and branched chain amino acids) to be fed into the first span of the CAC and
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Table 1. 1D 1H NMR Analysis Results Comparing the Metabolite
Profiles of Fh1 KO against Control Hearts
Metabolite
Fold Change,
Fh1/ versus WT T Test p
3-Hydroxybutyrate 1.844 0.0030
Alanine 1.230 0.0286
Fumarate 1.634 0.0044
Glutamate 0.829 0.0109
Glycine 1.153 0.0328
Isoleucine 1.298 0.0087
Lactate 1.26 0.034
Serine 1.288 0.0153
Succinate 1.817 6.72E-06
Taurine 0.893 0.0142
Valine 1.327 0.0002
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dependent transcriptional profile noted in Fh1 KO mice
(Hmox1, 1.63 ± 0.13, p < 0.05; Nqo1, 2.83 ± 0.63, p < 0.05;
Mthfd2, 1.13 ± 0.13, ns; Gsta1, 12.93 ± 3.53, p < 0.01) (Fig-
ure 5B), which translated to proteins as assessed by immuno-
blotting: Hmox1 (2.403 ± 0.273, p < 0.0001), Nqo1 (3.093 ±
0.333, p < 0.0001), Gsta3 (3.113 ± 0.183, p < 0.0001), and
Gsta1 (6.273 ± 0.433, p < 0.0001) (Figure 5C). Consistent with
our observations in the Fh1 KO hearts, DMF-treated animals
showed profoundly reduced myocardial necrosis when
compared to vehicle in the perfused heart model (9.3% ± 1.2%
versus 36.9% ± 3.9%, respectively; p < 0.0001) (Figure 5D)
and resulted in a more rapid recovery of coronary flow (mean
CF, 1.9 ± 0.05 versus 1.6 ± 0.04 ml/min; two-way ANOVA, p <
0.05) (Figure 5E). Finally, to assess the consequences of Nrf2
deletion on cardioprotection by DMF in vivo, 4-month-old WT
and Nrf2 knockout (Nrf2 KO) mice after oral DMF or vehicle treat-
ment underwent a coronary artery ligation model of myocardial
infarction (MI). DMF significantly reduced the size of the MI/
area at risk in WTmice compared to vehicle-treated WT controls
(p < 0.05 by ANOVAwith Bonferroni post hoc correction), but not
in the DMF-treated Nrf2 KO mice compared to vehicle-treated
Nrf2 KO controls (44.6% ± 3.9% versus 62.2% ± 3.9% and
63% ± 4.1% versus 57.9% ± 3.8%, respectively; p < 0.001 by
ANOVA), affirming the importance of Nrf2 to fumarate-related
cardioprotection (Figure 5F).
DISCUSSION
There is an increasing recognition that metabolites (e.g., succi-
nate), in addition to their roles in generating energy through inter-
mediary metabolism, have an important role in sensing andaspartate, via the malate-asparate shuttle, into the second span of the CAC. This
and porphyrin synthesis-heme degradation channeled through Hmox1.
(B) Nrf2 target genes and the genes coding for the related antioxidant enzymes
assessed by Taqman qRT-PCR. White bars, control; black bars, Fh1-KO.
(C) Representative immunoblots and densitometric analysis of Fh1-KO hearts d
Nqo1, Mthfdh2, Gsta3, and Gsta1.
(D) Fh1-KO hearts exhibit significantly increased levels of succination compared
(E) Hmox1 inhibition by ZnBG abrogates cardioprotection in Fh1-KO hearts as as
mean ± SEM. *p < 0.05; **p < 0.01; and ***p < 0.001 versus control.
Cemarshalling responses to diverse cellular stresses including I/R
injury (Sapieha et al., 2008). Accordingly, the present study
demonstrates that augmentation of myocardial fumarate,
whether through Fh1 depletion or by DMF treatment, is cardio-
protective. Predictions from an in silico model of the mito-
chondrial metabolome suggest that augmented anaplerotic
channeling of carbon moieties from amino acids into the CAC
contributes to the viability of Fh1-deficient hearts. These meta-
bolic adaptations, coupled with fumarate-related upregulation
of an Nrf2 antioxidant response—a response substantially reca-
pitulated by DMF—result in cardioprotection.
The surprisingly mild phenotype of renal (Pollard et al., 2007)
and cardiac Fh1 deficiency (despite an incomplete CAC) is not
easily explained by our current knowledge. In order to discern
the consequences of such metabolic perturbations, we used
a FBAmodel of metabolism to simulate the effect of Fh1 deletion
(Smith and Robinson, 2011). These simulations suggest that as
compensation for Fh1 depletion, there is substantial metabolic
remodeling, with likely carbon influx into the CAC from gluta-
mate/glutamine, aspartate, and branched chain amino acids
that reconstitutes and maintains oxidative flux. As a corollary,
our in vivo metabolic imaging (Schroeder et al., 2008, 2009),
biochemical measures of glycolysis, mitochondrial electron
chain complex activity, and myofiber oxygen consumption
studies confirm that Fh1 KO hearts largely maintain oxidative
metabolism. Our observation of increased steady-state lactate
levels in Fh1 KO hearts also raises the possibility of increased
glycolytic flux through LDH in Fh1KOhearts. However, our in vivo
assessment of LDH and PDH fluxes by [1-13C]pyruvate and
[2-13C]pyruvate, that might have been expected to show
increased LDH exchange flux in the context of increased
steady-state lactate, increased LDH activity, and/or increased
NADH:NAD+, did not confirm such an increased LDH flux (Wit-
ney et al., 2011). Nonetheless, the application of complimentary
techniques, including in vivo 18-fluorodeoxyglucose PET or
ex vivo perfusion with labeled glucose, along with measures of
lactate production, especially during stress, are needed to
confirm this observation. One mechanism contributing to the
maintenance of CAC activity, as predicted by the simulations,
is increased amino acid-derived anaplerosis (the nonoxidative
influx of metabolites into the CAC) as manifested by increased
label incorporation into aspartate and pyruvate in Fh1 KO hearts
perfused with [3-13C]glutamate. While metabolic inferences from
perfused hearts should be related to in vivo cardiac physiology
cautiously (due to the unphysiological substrate profile and
loading conditions used ex vivo), these observations underline
the potential importance of amino acid flux to Fh1 KO hearts.
We also report that fumarate potently increased the expres-
sion of antioxidant response element (ARE)-regulated genes
(e.g., Gsta1, Nqo1, and Hmox1) (Kwak et al., 2003; Hayesanaplerotic carbon flux is balanced by cataplerosis through succinate export
of one-carbon metabolism are significantly upregulated in Fh1-KO hearts as
emonstrating the downregulation of Keap1 and upregulation of Nrf2, Hmox1,
to WT.
sessed by the extent of necrosis resulting from ex vivo cardiac I/R. Values are
ll Metabolism 15, 361–371, March 7, 2012 ª2012 Elsevier Inc. 367
Figure 5. Administration of Fumarate Attenuates Ischemia-Reperfusion Injury
(A) Representative immunoblots and densitometric analysis of murine hearts gavaged with dimethylfumarate (DMF) at a dose of 15 mg/kg twice daily for 5 days,
demonstrating the upregulation of Nrf2 (left). DMF (10 mM) for 6 hr promoted nuclear translocation and localization of Nrf2 in HL-1 cells as assessed by confocal
microscopy (right).
(B) Oral DMF upregulates Nrf2 target genes as assessed by Taqman qPCR.
(C) Representative immunoblots (upper panel) and densitometric analysis (lower panel) of protein products of Nrf2 targets.
(D and E) Oral DMF treatment significantly attenuatedmyocardial necrosis resulting from ex vivo cardiac I/R and (E) was accompanied by an improved recovery in
coronary flow.
(F) To assess the cardioprotective effect of fumarate in vivo and the pertinence of Nrf2 to this protection, a coronary artery ligation model of acute MI was applied
toWT andNrf2-KOmice both treatedwith DMF and vehicle (n = 12 in each of the four groups). The average surgical mortality of coronary ligation surgery was 24%
and did not differ significantly across the groups.WT andNrf2-KOmice treatedwith vehicle (WT/V andNrf2-KO/V, respectively) or 5 days of DMF (15mg/kg) twice
daily (WT/F and Nrf2-KO/F, respectively) via oral gavage as above. Representative sections of the myocardium from each group are presented stained with 4%
TTC, with the necrotic area represented in white, the area at risk (AAR) in red, and the nonischemic area in blue. There was no significant difference in the size of
the underperfused area (AAR/LV) for each group (data not shown). While DMF reduced MI size in the WT animals treated with DMF compared to vehicle-treated
controls (MI/AAR by ANOVAwith Bonferroni post hoc comparison to vehicle-treatedWTmice), there was no difference in theMI size in Nrf2-KO-treated DMF and
vehicle-treated control mice, nor was there a difference in MI size as a percentage of the LV area. Values are mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001.
Cell Metabolism
Fumarate Cardioprotects via Activation of Nrf2et al., 2010) through activation of the redox-sensitive transcrip-
tion factor Nrf2 (Hayes and McMahon, 2009; Taguchi et al.,
2011). In the Fh1 KO hearts, the coregulated enzymes of one
carbon metabolism (e.g., Mthfd2) were also raised (He et al.,
2001; Harding et al., 2003; Adams, 2007; Afonyushkin et al.,
2010; Lewerenz andMaher, 2011). Unstimulated, Nrf2 is seques-
tered by Keap1, promoting Nrf2 ubiquitination and degradation.
During cell stress, Keap1, a cysteine-rich protein sensitive to
oxidants/electrophiles, is modified on one or more of its func-
tional cysteines (e.g., Cys151, Cys288, and Cys273), releasing the
sequestered Nrf2 and permitting Nrf2 to activate its target genes
(Taguchi et al., 2011).
FADs are known to be biologically active electrophiles and
inducers of glutathione transferases and NAD(P)H:quinone
reductases (Spencer et al., 1990). Recently, FADs have been368 Cell Metabolism 15, 361–371, March 7, 2012 ª2012 Elsevier Inc.shown to modify Cys151 and Cys288 of Keap1 in vitro (Linker
et al., 2011; Adam et al., 2011; Ooi et al., 2011). Although we
were unable to immunoprecipitate sufficient protein in vivo
from hearts to demonstrate Keap1 modification, using an anti-
body directed against (S-[2-succinyl] cysteine [2SC]) formed by
a reaction between fumarate and cysteines in proteins (Blatnik
et al., 2008), we demonstrated substantial 2SC modification in
Fh1 KO hearts (Figure 3D). Similar fumarate-dependent succina-
tion has been observed in FH-deficient cells and HLRCC cancer
tissuewith corresponding Nrf2 stabilization (Bardella et al., 2011;
Adam et al., 2011; Ooi et al., 2011). Thus, although we cannot
exclude other Nrf2-stabilizing influences (Rada et al., 2011),
given Keap1’s sensitivity to electrophiles and its proximity to
mitochondria (Lo and Hannink, 2008) (where fumarate concen-
trations are likely to be highest), coupled with increased
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Fumarate Cardioprotects via Activation of Nrf2succination and the findings in FH-deficient cells (Adam et al.,
2011; Ooi et al., 2011), we propose this represents strong, albeit
circumstantial evidence that Keap1 is succinated in fumarate-
replete hearts, explaining Nrf2 target gene upregulation by
both Fh1 deletion and DMF treatment. That DMF promotes
nuclear translocation of Nrf2 and that the protective properties
of DMF are abolished in Nrf2-KO mice further support our
proposal that Nrf2 has a central role in fumarate-related cardio-
protection in vivo.
To reconcile the cardioprotection noted in young Fh1-deficient
mice with the subsequent development of significant left ventric-
ular dysfunction after 3months of age, we propose that fumarate
accumulation triggers both adaptive and maladaptive re-
sponses, respectively. While Nrf2 activation is known to be
cardioprotective when acutely activated (Calvert et al., 2009;
Motohashi and Yamamoto, 2004; Zhang et al., 2010), there is
emerging evidence that chronic Nrf2 activation results in exper-
imental and human cardiomyopathy (Rajasekaran et al., 2007,
2011). Thus, while Nrf2 activation by fumarate is beneficial in
the context of ischemic stress, chronic Nrf2 activation is likely
to be harmful and cause heart failure. A similarly biphasic pattern
has been noted in animals with graded decrements in Keap1.
While Keap1(flox/) mice with increased Nrf2 levels are pro-
tected from the oxidative insults, a decrease in Keap1 levels to
<50% results of controls increased long-term mortality (Taguchi
et al., 2010).
A variety of interventions have been shown to reduce myocar-
dial infarct size in animals; however, these interventions have
translated poorly to man (Yellon and Hausenloy, 2007). While
other Nrf2 inducers may be cardioprotective, including sulfora-
phane (found in broccoli) (Mukherjee et al., 2008), hydrogen
sulphide (Calvert et al., 2009), and triterpenoid CDDO-imidazo-
lide (Sussan et al., 2009), they lack human safety data, may be
difficult to administer, and may have a low therapeutic index.
In contrast, we demonstrate that oral FADs, which have already
been successfully trialed in patients with psoriasis or multiple
sclerosis (Kappos et al., 2008), are cytoprotective agents. This
provides a strong rationale to investigate these safe and well-
tolerated agents in clinical trials, for example to assess the
impact of FADs in reducing myocardial injury in acute coronary
syndromes or in patients undergoing predictable organ injury,
e.g., surgery.EXPERIMENTAL PROCEDURES
Mouse Husbandry
Procedures involving live animals were in accordance with UK Home
Office guidelines and licensing regulations (project license 30/2444).
MLC2v-cre mice were a kind gift from Professor Ken Chien (Chen et al.,
1998). All mice were backcrossed onto a C57BL/6 genetic background
for at least five generations. Male 4-month-old Nrf2 knockout (KO; n =
24) and WT (n = 24) mice, all on a CD-1 genetic background, were obtained
from breeding colonies of the National Institute on Aging (Baltimore, MD).
The mice were maintained on a 12 hr light/dark cycle with food and water
available ad libitum. Experimental procedures were performed in accor-
dance with the UK Home office and National Institutes of Health guidelines
and approved by respective institutional review boards. In some experi-
ments, Fh1 KO mice were treated with a specific heme oxygenase-1
inhibitor, ZnBG, once daily (30 mg/kg, i.p.) for 4 days prior to heart cannu-
lation. For experiments investigating the role of oral FADs, C57Bl/6 mice
(Harlan) were gavaged (15 mg/kg) twice daily for 5 days with dimethylCefumarate (DMF; Sigma) diluted in 0.08% methocel/H2O before heart
cannulation.
Cardiac Magnetic Resonance Scans, Cine
Animals were imaged using a standard cine MR imaging protocol (TR/TE, 4.6/
1.755 ms; flip angle, 21; averages, 4; slice thickness, 1.2 mm; matrix, 128 3
128; zero filled to 2563 256; field of view, 51.23 51.2 mm). Scanning was per-
formed on seven to eight contiguous slices in the short-axis orientation
covering the entire heart. This was used to assess left ventricular mass and
cardiac function in the 7 T MR scanner (Schroeder et al., 2008).
In Silico Analysis
Simulations were performed using the mitochondrial metabolic model iAS253
(Smith and Robinson, 2011) that was modified to include cytosolic reactions
involved in the degradation of heme and an unconstrained boundary condition
to allow the efflux of bilirubin. Additional constraints were applied to the fuma-
rate and succinate inner mitochondrial membrane transport steps to represent
restricted transport (especially for fumarate, as a specificmammalian fumarate
transporter has not been identified). To determine the effect of increased
metabolite uptakes on central metabolism, separate simulations were per-
formed in which the allowable uptake range was increased. As uptake fluxes
for metabolites were not available under perturbed conditions, these ranges
were arbitrarily increased up to a maximum of 5 mmol/min/gDW. FBA was
used to simulate the system using MATLAB (MathWorks, Inc., Natick, MA)
and the COBRA toolbox in conjunction with the linear programming solver
GLPK (http://www.gnu.org/software/glpk/). The resultant flux distributions
were analyzed in Microsoft Excel and Cytoscape (Shannon et al., 2003).
Cardiac Magnetic Resonance Scans, Hyperpolarized 13Cs
Hyperpolarized 13C MRS Protocol [1-13C]pyruvate or [2-13C]pyruvate was
hyperpolarized and dissolved as previously described. An aliquot of 0.2 ml
of 80 mM hyperpolarized [1-13C]pyruvate or [2-13C]pyruvate solution was
then injected over 10 s via a tail vein catheter into an anaesthetised mouse
positioned in a 7 T MR scanner. Spectra were acquired for 1 min following
injection with 1 s temporal resolution, and signal was localized to the heart
using a home-built 13C RF surface coil. Quantified peak areas were input
into a kinetic model described by Atherton et al. (Atherton et al., 2011) and
plotted against time in Microsoft Excel. This model fits the spectral peak areas
as a function of time and accounts for several factors, including rate of injec-
tion, rate of signal decay for pyruvate and metabolites, and time of arrival for
pyruvate and metabolites. This model determines the rate constant for pyru-
vate to metabolite exchange (kpyr-x, s-1), which is a measure of 13C label
incorporation into lactate, alanine, or bicarbonate pools.
Statistics
All data are expressed as mean ± standard error of the mean (SEM). Statistical
analysis was performed using unpaired Student’s t test or one-way ANOVA fol-
lowed by the Bonferroni correction, where appropriate. Time course relation-
ships were evaluated using two-way ANOVA. Statistical analysis was carried
out using Graphpad Prism statistics software v.4. Differenceswere considered
significant when p < 0.05.
Standard molecular and histologic methodology is described in the Supple-
mental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two tables, six figures, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at doi:10.1016/j.cmet.2012.01.017.
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